Drugs / SUM-191
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07565103 | Jun 2026 → Aug 2028 expected | bacterial conjunctivitis | Senju USA, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUM-191 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07565103 ↗ |
| Route | Topical | “SUM-191 is administrated a single dose topically.” NCT07565103 ↗ |